Advice

in the absence of a submission from the holder of the marketing authorisation

metformin hydrochloride (Glucophage SR®) is not recommended for use within NHS Scotland.

Indication under review: Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are:
• at high risk for developing overt type 2 diabetes mellitus and
• still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice190KB (PDF)

Download

Medicine details

Medicine name:
metformin hydrochloride (Glucophage)
SMC ID:
1308/18
Indication:
Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.
Pharmaceutical company
Merck Serono Ltd
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published
15 January 2018